Background: The SARS-CoV-2 pandemic in the UK triggered a national characterisation protocol and information on co-morbidities including malignant neoplasm is recorded A lack of prospective data regarding cancer patients with COVID-19 hampers the development of an evidence based approach in this population The Clinical Characterisation Protocol-CANCER-UK is a UK multi-disciplinary project aimed at characterising the presentation and course of COVID-19 in cancer patients with the aim of informing practice Methods: The international Severe Acute Respiratory and emerging Infections Consortium (ISARIC)-4C COVID-19 Clinical Information Network (CO-CIN) collects data on hospital inpatients with proven/high likelihood of COVID-19 Data was collected in 166 UK sites using a questionnaire adopted by the WHO Data on patients with malignant neoplasm was extracted from the main dataset We chose a priori to restrict any analysis of outcome to patients who were admitted more than 14 days before data extraction (13th May 2020) Results: As of 13th May 2020 1797 of 16160 participants had malignant neoplasm (8 6% of all cases) Age&lt;50 62 (3 5%), 50-60 378 (21%), 70-79 558 (31%), 80+ 1002 (42%) Male 1147 (64%);Female 645 (36%) Commonest comorbidities chromic pulmonary disease (22%), chronic kidney disease (21%), uncomplicated diabetes (19%) and dementia (14%) Outcomes 35% discharged alive, 30% care ongoing & 35% died Admiited to ICU: 150 cases (25% discharged alive,31% care ongoing & 45% died) Receiving invasive ventiation: 67 cases (18% discharged alive, 25% care ongoing:25% & 57% died) HR mortality for malignancy (adjusted for age, sex, other comorbidity): 1 13 (1 02-1 24, p=0 017) Data on presentation will be presented Conclusions: Europe’s largest prospective COVID-19 dataset demonstrates that cancer is independently associated with mortality in patients admitted with COVID-19 Data collection is on-going and updated data will be presented including a comparison of cancer vs non-cancer cohort with regard to presentation, comorbidity and otucomes Clinical trial identification: ISRCTN66726260 Legal entity responsible for the study: and international Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Coronavirus Clinical Characterisation Consortium (ISARIC4C) Funding: UK Research and Innovation, Medical Research Council and Department for Health and Social Care Disclosure: All authors have declared no conflicts of interest
Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium